Plant Name: Urtica dioica
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| HRH1; HRH2; HTR1F; HTR4; HTR1B; HTR1D; ADORA3; HTR7; HTR5A; HTR1E; HTR2B; HTR2A; HTR2C; HTR6; HRH3; HRH4; DRD3; DRD4; DRD2; HTR1A; | |
| TSHR; NPSR1; CXCR1; | |
| RECQL; TDP1; PLA2G1B; CTDSP1; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; GFER; AKR1B10; NOX4; PYGL; POLB; | |
| PTPN1; | |
| HTR3A; | |
| NEK6; PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; IGF1R; PTK2; AURKB; GSK3B; CDK1; PIM1; NUAK1; ALK; SRC; AXL; KDR; | |
| CA14; CA5B; CA3; CA7; CA5A; CA1; CA12; CA9; CA4; CA6; CA2; | |
| AR; | |
| ESRRA; | |
| KDM4E; | |
| MAOA; ALOX5; TYR; XDH; | |
| CASP7; CASP1; | |
| MMP13; MMP3; MMP2; MMP9; MMP1; | |
| BACE1; | |
| AHR; STAT6; HIF1A; NFKB1; TP53; | |
| ABCC1; ABCG2; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| 5HT3 receptor | HTR3A | Serotonin 3a (5-HT3a) receptor | P46098 | CHEMBL1899 |
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Small molecule receptor (family A GPCR) | HRH1 | Histamine H1 receptor | P35367 | CHEMBL231 |
| Small molecule receptor (family A GPCR) | HRH2 | Histamine H2 receptor | P25021 | CHEMBL1941 |
| Small molecule receptor (family A GPCR) | HTR1F | Serotonin 1f (5-HT1f) receptor | P30939 | CHEMBL1805 |
| Small molecule receptor (family A GPCR) | HTR4 | Serotonin 4 (5-HT4) receptor | Q13639 | CHEMBL1875 |
| Small molecule receptor (family A GPCR) | HTR1B | Serotonin 1b (5-HT1b) receptor | P28222 | CHEMBL1898 |
| Small molecule receptor (family A GPCR) | HTR1D | Serotonin 1d (5-HT1d) receptor | P28221 | CHEMBL1983 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | HTR7 | Serotonin 7 (5-HT7) receptor | P34969 | CHEMBL3155 |
| Small molecule receptor (family A GPCR) | HTR5A | Serotonin 5a (5-HT5a) receptor | P47898 | CHEMBL3426 |
| Small molecule receptor (family A GPCR) | HTR1E | Serotonin 1e (5-HT1e) receptor | P28566 | CHEMBL2182 |
| Small molecule receptor (family A GPCR) | HTR2B | Serotonin 2b (5-HT2b) receptor | P41595 | CHEMBL1833 |
| Small molecule receptor (family A GPCR) | HTR2A | Serotonin 2a (5-HT2a) receptor | P28223 | CHEMBL224 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | HTR6 | Serotonin 6 (5-HT6) receptor | P50406 | CHEMBL3371 |
| Small molecule receptor (family A GPCR) | HRH3 | Histamine H3 receptor | Q9Y5N1 | CHEMBL264 |
| Small molecule receptor (family A GPCR) | HRH4 | Histamine H4 receptor | Q9H3N8 | CHEMBL3759 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Small molecule receptor (family A GPCR) | HTR1A | Serotonin 1a (5-HT1a) receptor | P08908 | CHEMBL214 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.792E-12 | 2.628E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.220E-12 | 2.764E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.720E-12 | 3.233E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, MPO, NOX4, SRC |
| MF | Unclassified; | GO:0004872; receptor activity | 1.183E-11 | 4.521E-09 | ADORA3, AHR, ALK, AR, AXL, CXCR1, DRD2, DRD3, DRD4, ESRRA, FLT3, HRH1, HRH2, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, TSHR |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 2.413E-11 | 8.082E-09 | ABCC1, ADORA3, ALK, AXL, BACE1, DRD2, DRD3, DRD4, FLT3, HRH1, HRH2, HRH3, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.116E-11 | 9.833E-09 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0004969; histamine receptor activity | 3.116E-11 | 9.833E-09 | HRH1, HRH2, HRH3, HRH4, HTR6 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.411E-11 | 1.040E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2D6, CYP3A4 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 3.930E-11 | 1.141E-08 | ADORA3, ALK, AXL, CXCR1, DRD2, DRD3, DRD4, FLT3, HRH1, HRH2, HRH3, HRH4, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7, IGF1R, KDR, MET, NPSR1, TSHR |
| BP | GO:0009987; cellular process | GO:0007198; adenylate cyclase-inhibiting serotonin receptor signaling pathway | 9.594E-10 | 2.132E-07 | HTR1A, HTR1B, HTR5A, HTR7 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 9.594E-10 | 2.132E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.423E-09 | 2.951E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.003E-09 | 7.388E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.003E-09 | 7.388E-07 | CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.521E-08 | 3.786E-06 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, GLO1, MMP1, MMP13, MMP2, MMP3, MMP9, PTPN1, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 2.645E-08 | 3.945E-06 | CA2, CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C, KDR, NPSR1, PLA2G1B, SRC |
| BP | GO:0050896; response to stimulus | GO:0034776; response to histamine | 3.071E-07 | 3.377E-05 | DRD2, DRD3, DRD4, HRH1 |
| BP | GO:0009987; cellular process | GO:0002031; G-protein coupled receptor internalization | 3.071E-07 | 3.377E-05 | DRD2, DRD3, HTR1B, HTR2B |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 4.641E-07 | 4.906E-05 | AURKB, CA2, CA7, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR2C, KDR, NEK2, NPSR1, PLA2G1B, SRC |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 5.281E-07 | 5.528E-05 | ABCC1, ABCG2, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 7.886E-07 | 7.805E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0065007; biological regulation | GO:0007194; negative regulation of adenylate cyclase activity | 9.304E-07 | 8.801E-05 | DRD2, DRD3, DRD4, HRH3, HRH4 |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 1.655E-06 | 1.441E-04 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0010513; positive regulation of phosphatidylinositol biosynthetic process | 1.734E-06 | 1.486E-04 | HTR2A, HTR2B, HTR2C |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.734E-06 | 1.486E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 2.310E-06 | 1.947E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 2.315E-06 | 1.947E-04 | AKT1, HIF1A, HRH1, HTR2A, NFKB1, SRC |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.453E-06 | 2.795E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.520E-06 | 2.839E-04 | MMP1, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 4.220E-06 | 3.304E-04 | CA3, CDK1, DRD3, HTR1B, HTR3A, POLB, TP53 |
| BP | GO:0007610; behavior | GO:0048148; behavioral response to cocaine | 4.336E-06 | 3.372E-04 | DRD2, DRD3, DRD4, HTR2A |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 4.371E-06 | 3.378E-04 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 5.191E-06 | 3.863E-04 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.421E-06 | 4.001E-04 | AURKB, CA2, CA7, DRD2, DRD3, HIF1A, NEK2, NPSR1, PLA2G1B |
| BP | GO:0032502; developmental process | GO:0007568; aging | 6.471E-06 | 4.635E-04 | AKT1, AURKB, CDK1, CYP1A1, HTR2A, MPO, NOX4, POLB, TP53 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 7.364E-06 | 5.189E-04 | DRD2, DRD3, HIF1A, HRH1, HRH2 |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 7.821E-06 | 5.441E-04 | DRD2, DRD3, DRD4, PLA2G1B |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 9.161E-06 | 6.234E-04 | HIF1A, MMP1, MMP13, MMP2, MMP3, MMP9 |
| MF | GO:0060089; molecular transducer activity | GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go | 9.589E-06 | 6.445E-04 | DRD2, DRD3, DRD4 |
| MF | GO:0005488; binding | GO:0051378; serotonin binding | 1.100E-25 | 7.983E-22 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR3A, HTR5A, HTR7 |
| BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 1.600E-05 | 1.016E-03 | ALOX15, DRD2, HTR2A, HTR2B, HTR2C, KDR, NOX4, SRC |
| BP | GO:0008152; metabolic process | GO:0042417; dopamine metabolic process | 1.770E-05 | 1.107E-03 | DRD2, DRD3, DRD4, MAOA |
| BP | GO:0009987; cellular process | GO:0014059; regulation of dopamine secretion | 1.770E-05 | 1.107E-03 | DRD2, DRD3, HTR1B, HTR2A |
| BP | GO:0009987; cellular process | GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway | 2.038E-05 | 1.243E-03 | DRD2, DRD3, DRD4 |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 2.414E-05 | 1.448E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.992E-05 | 1.737E-03 | AKT1, AR, CASP7, CYP1A1, CYP1B1, FLT3, HRH1, NFKB1, NOX4, SRC |
| BP | GO:0023052; signaling | GO:0032228; regulation of synaptic transmission, GABAergic | 3.054E-05 | 1.750E-03 | CA2, CA7, DRD2, HTR1B |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.054E-05 | 1.750E-03 | AHR, CSNK2A1, HIF1A, KDR |
| BP | GO:0009987; cellular process | GO:0007208; phospholipase C-activating serotonin receptor signaling pathway | 3.155E-05 | 1.780E-03 | HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.155E-05 | 1.780E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.155E-05 | 1.780E-03 | ALOX12, ALOX15 |
| MF | GO:0005488; binding | GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding | 3.155E-05 | 1.780E-03 | HTR2A, HTR2C |
| BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 3.292E-05 | 1.847E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 3.461E-05 | 1.927E-03 | AKT1, HRH1, HRH2, HTR2A |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 4.798E-05 | 2.599E-03 | CYP19A1, HSD17B1, HSD17B2 |
| MF | GO:0005488; binding | GO:0035240; dopamine binding | 4.798E-05 | 2.599E-03 | DRD2, DRD3, DRD4 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 5.404E-05 | 2.877E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0023052; signaling | GO:0051967; negative regulation of synaptic transmission, glutamatergic | 6.081E-05 | 3.167E-03 | DRD2, HTR1B, HTR2A |
| BP | GO:0009987; cellular process | GO:0097194; execution phase of apoptosis | 6.108E-05 | 3.167E-03 | AKT1, CASP1, CASP7, PTK2 |
| BP | GO:0009987; cellular process | GO:1903201; regulation of oxidative stress-induced cell death | 6.167E-05 | 3.182E-03 | AKT1, HIF1A, MET, MMP3, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 8.437E-05 | 4.223E-03 | MMP1, MMP13, MMP2, MMP3, MMP9 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 8.935E-05 | 4.452E-03 | ABCC1, CA2, CA4, CA9, SLCO1B1, SLCO1B3, TSHR |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.279E-05 | 4.574E-03 | ALOX12, ALOX15, ALOX5 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 9.431E-05 | 4.574E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0060160; negative regulation of dopamine receptor signaling pathway | 9.431E-05 | 4.574E-03 | DRD2, DRD3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.431E-05 | 4.574E-03 | CA2, CA7 |
| BP | GO:0023052; signaling | GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission | 9.431E-05 | 4.574E-03 | DRD2, DRD4 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 9.431E-05 | 4.574E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 9.431E-05 | 4.574E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 9.431E-05 | 4.574E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 1.095E-04 | 5.250E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.122E-04 | 5.335E-03 | CYP2C19, CYP2C8, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.122E-04 | 5.335E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0065007; biological regulation | GO:0051336; regulation of hydrolase activity | 1.167E-04 | 5.511E-03 | AKT1, ALDH1A1, CASP1, CASP7, CSNK2A1, DAPK1, DRD2, GSK3B, HTR2A, HTR2B, MMP9, NUAK1, PLA2G1B, PTK2, PTPN1, SRC, TP53, XDH |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.196E-04 | 5.577E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0051179; localization | GO:0051209; release of sequestered calcium ion into cytosol | 1.196E-04 | 5.577E-03 | DRD2, HTR2A, HTR2B, HTR2C |
| BP | GO:0048511; rhythmic process | GO:0007623; circadian rhythm | 1.219E-04 | 5.661E-03 | AHR, DRD2, DRD3, GSK3B, HTR7, TP53 |
| BP | GO:0008152; metabolic process | GO:0051000; positive regulation of nitric-oxide synthase activity | 1.341E-04 | 6.173E-03 | AKT1, HIF1A, HTR2B |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.420E-04 | 6.494E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 1.605E-04 | 7.327E-03 | ALK, CDK1, DRD4, PKN1, PLA2G1B, PTPN1 |
| BP | GO:0050896; response to stimulus | GO:0006954; inflammatory response | 1.771E-04 | 8.049E-03 | ADORA3, AKT1, ALOX15, AXL, CXCR1, HRH1, HRH4, NFKB1, NOX4, POLB |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 1.835E-04 | 8.305E-03 | AKT1, ALOX15, AXL, CASP1, DAPK1, FLT3, GSK3B, HIF1A, NFKB1 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.859E-04 | 8.368E-03 | ALOX15, AURKB, DRD3, GSK3B, HIF1A, KDR, MET, MMP9, NEK2, NOX4, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.879E-04 | 8.368E-03 | CYP1A1, CYP1A2 |
| BP | GO:0032501; multicellular organismal process | GO:0014827; intestine smooth muscle contraction | 1.879E-04 | 8.368E-03 | HTR1D, HTR2B |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 1.879E-04 | 8.368E-03 | ALDH1A1, AR |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.019E-04 | 8.902E-03 | AKT1, HIF1A, MMP9, PTPN1, SRC |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.159E-04 | 9.402E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 2.236E-04 | 9.681E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.473E-22 | 5.347E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0009987; cellular process | GO:0007210; serotonin receptor signaling pathway | 1.428E-21 | 3.109E-18 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| MF | GO:0060089; molecular transducer activity | GO:0004993; G-protein coupled serotonin receptor activity | 1.428E-21 | 3.109E-18 | HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR4, HTR5A, HTR6, HTR7 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.231E-16 | 8.287E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.828E-15 | 5.256E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.810E-14 | 4.685E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP3A4, NOX4 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.303E-27 | 1.314E-24 | HTR1E; HTR1F; MAOA; HTR1D; ALOX15; HTR1A; HTR2B; HTR1B; HTR2C; ALOX12; HTR3A; HTR2A; HTR5A; CYP2C19; HTR4; CYP2C9; CYP2C8; HTR6; HTR7; CYP2D6; ALOX5 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.236E-18 | 1.341E-16 | HTR1E; HTR1F; HTR1D; HTR1A; HTR2B; HTR1B; HTR2C; HTR2A; HTR5A; HTR4; TSHR; HTR6; HRH1; HTR7; HRH3; HRH2; ADORA3; HRH4; DRD2; DRD3; DRD4 |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 9.034E-22 | 8.130E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 6.405E-11 | 2.882E-09 | CAMK2B; HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; PIK3R1; HTR4; NFKB1; TSHR; HTR6; AKT1; DRD2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.143E-09 | 3.429E-08 | CAMK2B; SRC; MMP2; KDR; AKT1; PIK3R1; TP53; HIF1A; MMP9; MET; PTK2; IGF1R |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 4.187E-09 | 1.077E-07 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; AKT1; MET; TP53 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.661E-10 | 5.981E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 9.679E-09 | 2.178E-07 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 5.362E-08 | 8.773E-07 | CAMK2B; HTR6; HRH1; HTR7; HRH2; HTR2B; HTR2C; HTR2A; HTR5A; HTR4 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 6.290E-08 | 9.435E-07 | CAMK2B; HRH1; SRC; HTR2B; HTR2C; ALOX12; PIK3R1; HTR2A |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.517E-08 | 8.130E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.811E-08 | 5.623E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 9.604E-08 | 1.235E-06 | CYP2C9; CYP2C8; MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.610E-07 | 6.311E-06 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 8.781E-08 | 1.216E-06 | MMP1; DAPK1; SRC; MMP2; MMP9; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 6.244E-07 | 6.611E-06 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.920E-06 | 2.503E-05 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; AKR1B10; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; XDH |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.193E-07 | 3.832E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.738E-06 | 1.646E-05 | FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.451E-06 | 1.451E-05 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 6.808E-06 | 5.328E-05 | CAMK2B; GSK3B; MAOA; AKT1; DRD2; DRD3; DRD4 |
| hsa04742 | Taste transduction_Homo sapiens_hsa04742 | 6.124E-06 | 5.011E-05 | HTR1E; HTR1F; HTR1D; HTR1A; HTR1B; HTR3A |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.887E-06 | 2.503E-05 | CYP2C9; CYP2D6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.742E-05 | 1.081E-04 | GSK3B; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 8.051E-06 | 6.038E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 1.497E-05 | 9.841E-05 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.531E-05 | 9.841E-05 | SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.602E-06 | 6.193E-05 | SRC; CDK1; HTR2B; HTR2C; HTR2A; DRD2 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.457E-05 | 1.778E-04 | HTR7; PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.465E-05 | 9.841E-05 | FLT3; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.124E-05 | 1.234E-04 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.086E-05 | 1.634E-04 | CASP7; MMP3; AKT1; PIK3R1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 2.930E-05 | 1.598E-04 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 2.046E-05 | 1.227E-04 | SRC; KDR; AKT1; PIK3R1; PTK2 |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.792E-05 | 1.570E-04 | CAMK2B; AKT1; PIK3R1; TP53; IGF1R |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 4.583E-05 | 2.118E-04 | GSK3B; SRC; AKT1; PIK3R1; TP53; HIF1A |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 5.036E-05 | 2.211E-04 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 7.450E-05 | 3.048E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.288E-05 | 2.086E-04 | AKT1; PIK3R1; TP53; MET; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.036E-05 | 2.211E-04 | ABCC1; ADORA3; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 1.206E-04 | 4.524E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.185E-04 | 4.524E-04 | CASP7; LMNA; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 4.588E-05 | 2.118E-04 | GSK3B; SRC; AKT1; PIK3R1; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.010E-04 | 4.039E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 1.580E-04 | 5.803E-04 | SRC; KDR; AKT1; PIK3R1; DRD2; MET; IGF1R |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.288E-05 | 2.086E-04 | SLCO1B1; CA2; SLCO1B3; CYP3A4; ABCG2 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 5.237E-05 | 2.244E-04 | PTPN1; CSNK2A1; SRC; MET; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.292E-04 | 7.784E-04 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.075E-04 | 4.207E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.637E-04 | 5.893E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.087E-04 | 7.226E-04 | SRC; MMP2; AKT1; PIK3R1; MMP9 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 9.092E-04 | 2.557E-03 | POLB; SRC; CDK1; PIK3R1; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.216E-03 | 3.317E-03 | ABCC1; PIM1; CYP1B1; TP53; MMP9; MET; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 8.104E-04 | 2.353E-03 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.428E-03 | 3.837E-03 | GSK3B; CASP7; AKT1; PIK3R1; NFKB1 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 9.881E-04 | 2.736E-03 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 2.911E-03 | 7.277E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 2.720E-03 | 6.895E-03 | GSK3B; CASP1; AKT1; PIK3R1; NFKB1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.035E-03 | 5.387E-03 | CDK1; AKT1; PIK3R1; IGF1R |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.805E-04 | 2.008E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.527E-03 | 6.498E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.805E-04 | 2.008E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 4.639E-04 | 1.440E-03 | AKT1; PIK3R1; MET; HIF1A |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 3.979E-03 | 9.425E-03 | ALOX5; AKT1; PIK3R1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 4.639E-04 | 1.440E-03 | AKT1; PIK3R1; TP53; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 7.624E-03 | 1.672E-02 | GSK3B; AKT1; PIK3R1; IGF1R |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 4.611E-03 | 1.064E-02 | CAMK2B; AR; CDK1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 7.624E-03 | 1.672E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.099E-02 | 2.327E-02 | PIM1; AKT1; STAT6; PIK3R1 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.376E-02 | 2.723E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 8.734E-04 | 2.495E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 3.979E-03 | 9.425E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.848E-04 | 6.521E-04 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 3.651E-04 | 1.174E-03 | GSK3B; AKT1; PIK3R1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 2.465E-04 | 8.217E-04 | ALK; AKT1; PIK3R1; TP53 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 5.199E-04 | 1.586E-03 | CXCR1; SRC; MET; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.351E-02 | 2.704E-02 | BACE1; GSK3B; CASP7; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.638E-02 | 3.147E-02 | CAMK2B; SRC; AKT1; NFKB1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.859E-02 | 3.380E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.738E-02 | 3.258E-02 | CAMK2B; GSK3B; TYR |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.352E-02 | 2.704E-02 | CAMK2B; SRC; MMP2 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.913E-02 | 4.947E-02 | SRC; AKT1; PIK3R1 |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.284E-02 | 4.031E-02 | CAMK2B; AKT1; PIK3R1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.784E-02 | 3.277E-02 | AKT1; PIK3R1; HIF1A |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.026E-02 | 3.610E-02 | AKT1; PIK3R1; NFKB1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.784E-02 | 3.277E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.738E-02 | 3.258E-02 | PIK3R1; NFKB1; PTK2 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.927E-02 | 3.468E-02 | AKT1; PIK3R1; NFKB1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.162E-02 | 2.403E-02 | CASP1; PKN1; NFKB1 |
| hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 7.711E-03 | 1.672E-02 | CAMK2B; HRH2; CA2 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 6.558E-05 | 2.745E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 8.001E-03 | 1.714E-02 | CASP7; CASP1; NFKB1 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.154E-03 | 1.174E-02 | AKT1; PIK3R1; IGF1R |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.300E-03 | 1.005E-02 | AKT1; PIK3R1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 3.539E-03 | 8.608E-03 | AKT1; PIK3R1; TSHR |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 3.362E-03 | 8.291E-03 | CASP7; CASP1; NFKB1 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.418E-03 | 6.307E-03 | MAOA; DRD2; NFKB1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.502E-02 | 4.330E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.607E-02 | 4.469E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.399E-02 | 4.193E-02 | ABCC1; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.159E-02 | 2.403E-02 | AKR1B10; AKR1B1 |
| hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.558E-02 | 3.047E-02 | MAOA; TYR |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.312E-02 | 2.684E-02 | AKR1B10; AKR1B1 |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.643E-02 | 3.147E-02 | AKR1B10; AKR1B1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.910E-03 | 1.555E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.912E-04 | 9.529E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| H60-H95: Diseases of the ear and mastoid process | Vertigo meniere's disease | H81, H81.0, R42 | HRH1 |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep maintenance insomnia | F51.0, G47.0 | HTR2A |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | HRH1; HRH1; PLA2G1B; ALOX5 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; HTR2A; HTR2C; HRH3; DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
| NA: NA | Vomiting | NA | HRH1; HTR3A; DRD2 |
| NA: NA | Vertigo's disease | NA | HRH1 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Lateral sclerosis | G12.2 | HTR1A |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| NA: NA | Meniere's disease | NA | HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| NA: NA | Bulimia nervosa | NA | HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR1B; HTR2C; DRD3; DRD4; DRD2; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychoses | F20-F29 | HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | HTR2A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Allergic skin disorders | L00-L99 | HRH1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | HRH1; HRH1; PLA2G1B; ALOX5; DRD2 |
| NA: NA | Allergic disorders | NA | HRH1 |
| C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | HRH1; HRH1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| NA: NA | Vasomotor rhinitis | NA | HRH1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Local anaesthetic | R20.0 | HTR3A |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| I00-I99: Diseases of the circulatory system | Cerebral infarction | I63 | HTR2B |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | HTR2A; HRH3 |
| NA: NA | Cervical dystonia | NA | HTR1A |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Severe mood disorders | F30-F39 | HTR1D; HTR1A; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sleep disorders | F51, G47 | HRH1; HTR7; HTR2A; HRH3 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; HTR1B; HTR7; HTR1D; HTR2C; HTR2C; DRD2; HTR1A; HTR1A |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2 |
| NA: NA | Male hypogonadism | NA | AR |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; HTR2A; KDR |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2 |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Spasm | R25.2 | HTR1A |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MMP9; TP53; KDR; KDR; KDR |
| NA: NA | Social phobia | NA | HTR1A |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; KDR; KDR |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2 |
| NA: NA | Malignant essential hypertension | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | AR; HRH1; AKT1; MET; CSNK2A1; CA1; FLT3; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MMP9; NFKB1; PIM1; TP53; KDR |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2 |
| NA: NA | Peripheral sensory neuropathies | NA | HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; ALOX5; CASP1; MMP3; HRH4; TYR; MMP1 |
| NA: NA | Addiction | NA | HTR2A |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C; HRH3 |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC |
| NA: NA | Schizoaffective disorder | NA | HTR1A |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Seasonal and perennial allergic rhinitis and vasomotor rhinitis | J30 | HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; HTR7; HTR2A; HTR2A; HTR2C; HTR6; HRH3; HRH3; DRD3; DRD4; DRD2; DRD2; DRD2; DRD2; HTR1A; HTR1A |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | HTR2A; HTR3A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; CASP1; DRD2 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR1B; HTR1D; HTR2C; DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | HTR1F; HTR1D; HTR2B; HTR2A; CYP2D6; HTR1A |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | HRH3 |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2 |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; DRD2; DRD2; DRD2 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | HTR1A |
| NA: NA | Primary insomnia | NA | HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ADORA3; HTR2A; DRD2 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | HRH2; MMP9 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
| C00-D49: Neoplasms | Breast cancer | C50 | AR; FLT3; FLT3; CA9; IGF1R; CYP19A1; CDK1; DRD2; KDR; KDR; KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C; HTR1A; HTR1A |
| K00-K95: Diseases of the digestive system | Gastric ulcer | K25 | HRH2 |
| K00-K95: Diseases of the digestive system | Gastric secretory disorders | K30 | HRH2 |
| K00-K95: Diseases of the digestive system | Gastroesophageal reflux disease | K21 | HRH2; HTR3A |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD2 |
| K00-K95: Diseases of the digestive system | Stomach ulcer | K25-K27 | HRH2 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; HTR2B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Anesthesia | R20.0 | HRH1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| J00-J99: Diseases of the respiratory system | Hay fever | J30 | HRH1; HRH1; HRH1 |
| NA: NA | Itching | NA | HRH1; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HRH1; MAOA; HTR2B; HTR2A; HTR2C; HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; GSK3B; HTR2A; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | HTR1A |
| NA: NA | False perceptions | NA | DRD2 |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; DRD2 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; HRH4; DRD2 |
| NA: NA | Episode | NA | HTR1A |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| I00-I99: Diseases of the circulatory system | Hemorrhoids | I84 | HTR2A |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| NA: NA | Peripheral vasoconstriction | NA | DRD2 |
| H00-H59: Diseases of the eye and adnexa | Ocular allergy | H00-H59 | HRH1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3; HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | HTR1D |
| I00-I99: Diseases of the circulatory system | Coronary heart disease | I25.1 | HTR2B |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2 |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR1B; HTR1D; HTR2A; HTR2C; HTR1A |
| NA: NA | Morning sickness | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2 |
| NA: NA | Hypersensitivity reactions | NA | HRH1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD2; DRD2; HTR1A |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | HRH1; PLA2G1B; ESRRA; ALOX5; ALOX5; HRH4; DRD2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; MMP1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Erythropoietic porphyria | E80.0 | HTR2A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; CASP1; HTR1D; HRH3 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| NA: NA | Corneal vascularity | NA | DRD2 |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | HTR6 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2 |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| NA: NA | Hyperaemia | NA | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | HRH3 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Excessive daytime sleepiness | F51.1, G47.1 | HRH3 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| I00-I99: Diseases of the circulatory system | Congestive heart failure | I50 | HTR2B |
| NA: NA | Common cold | NA | HRH1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2 |
| NA: NA | Coughs | NA | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Eating disorder | E66, F50, I10-I16, I50 | HRH3; HTR1A |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | HRH2; CA1; CA2 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
| NA: NA | Perennial and seasonal allergic rhinitis | NA | HRH1 |
| K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | HRH2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Musculoskeletal pain | R52, G89 | HRH3 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Hypoactive sexual desire disorder | F52.0 | HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | HTR6; HTR3A; DRD3; DRD2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Schizoaffective disorders | NA | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obese insulin-resistant disorders | E11 | HRH3 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; DRD2; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HRH1; PTPN1; HTR2C; HTR2C; HTR6; HRH3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; HRH3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Dry cough | R05 | HRH1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; DRD3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; GSK3B; HTR6; HTR6; HTR6; HRH3; HRH3; DRD2; HTR1A; HTR1A |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | HRH1; HRH1; HRH1; HRH1; HRH1; PLA2G1B; ESRRA; HRH3; HRH4 |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | HRH1; DRD2 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| G00-G99: Diseases of the nervous system G00-G99 | Narcolepsy | G47.4 | HRH3 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | HRH1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; HTR2C; HTR6; HRH3 |
| K00-K95: Diseases of the digestive system | Acid-reflux disorders | K21 | HRH2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | HTR6; HRH3; HRH3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | HRH1; HRH1; ALOX5 |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| NA: NA | Inflammatory diseases | NA | DRD2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | HRH1; HRH1; CYP2D6; CA2; DRD2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | HTR6; HRH3; HTR1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Chronic schizophrenics | F20 | HTR1B |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; DRD2 |
| K00-K95: Diseases of the digestive system | Pancreatitis | K85, K86.0K86.1 | HTR2A |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | HRH1; MPO; MAOA; DRD2; HTR1A |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; HRH1; HRH2; MMP13; IGF1R; CDK1; HTR2C; HRH3; HRH3; DRD2; HTR1A |
| NA: NA | Urticaria | NA | HRH1; HRH1; HRH1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | HRH1; HRH1; HTR3A; HTR3A; DRD2 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | HRH1; ALOX5 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| NA: NA | Respiratory allergies | NA | HRH1; HRH1 |
| NA: NA | Anxiety disorders | NA | HTR1A |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | HRH1; HRH1; HRH1; CAMK2B; MAOA; HTR1B; HTR2A; HTR2C; HTR6; HTR6; HRH3; CYP3A4; DRD2; HTR1A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| A00-B99: Certain infectious and parasitic diseases | Irritable bowel syndrome | A09, K58, K59.1 | HTR2B; HTR3A |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |